CanaQuest Medical Corp Overview
– a clinical-stage life sciences company
CanaQuest Medical Corp. (CANQF) is a clinical-stage life sciences company that specializes in developing innovative cannabinoid-based therapeutics. The company’s primary focus is on CQ-001, a proprietary drug candidate that combines cannabidiol (CBD) with essential fatty acids (Omega-3s). Prior research and animal studies have demonstrated CQ-001’s synergistic effects and enhanced ability to bind to critical “PPAR” receptors in the brain, which play a key role in cellular regulation and metabolism. This formulation has shown increased potency and effectiveness in addressing epilepsy.
Drug Candidate – CQ-001: CQ-001 has the potential to offer superior benefits compared to existing treatments like Epidiolex® at lower dosages and with reduced side effects. The drug aims to treat neurological conditions such as epilepsy, PTSD, and anxiety. CanaQuest’s advanced research and promising pre-clinical results position it as a leader in next-generation cannabinoid therapies, presenting a compelling investment opportunity.
Pre-Clinical Trials: Pre-clinical trials on rodents were successfully completed at Western University. A pre-clinical MES model of epilepsy conducted on mice at the Ontario Brain Institute revealed that CQ-001 demonstrated a 35% increase in potency compared to isolated cannabidiol alone. This indicates that the drug is significantly more effective at protecting against seizure activity.
Synergistic Effect: The combination of cannabidiol and the proprietary API composition in CQ-001 demonstrated potentiation, resulting in an effect greater than the sum of the individual effects of cannabidiol or the proprietary API alone. This suggests the potential for using lower dosages to achieve similar efficacy, potentially translating to a safer side effect profile.
Accumulated Expertise: To commercialize and obtain relevant regulatory approvals for CQ-001, CanaQuest has gathered a strong team of consultants and advisors with extensive experience in cannabinoid therapeutics, including:
1. Acting Chief Scientific Officer – Dr. Jordyn Stuart, Ph.D., BS, BS: With 12 years of pre-clinical cannabinoid research experience, including 6 years with Greenwich Biosciences (subsidiary of GW Pharma, now Jazz Pharma), Dr. Stuart has been involved in the launch of Epidiolex®.
2. Chairman of Advisory Board – Dr. Paul Dick, DVM, MSc: With over 30 years of experience in the pharmaceutical and animal health industries, Dr. Dick has served on several boards, including the Animal Health Institute and the Ontario Veterinary Medical Association.
3. Interim Chief Operating Officer – Eddie Francis, MS: With a background in Molecular Biology and Oncology, Eddie has over 10 years of experience in the natural therapeutic sector and 20 years in the private sector, focusing on mental health and wellness initiatives.
We have also secured ongoing relationships with trusted legal, regulatory, and compliance advisors who will help move our business forward.
Regulatory Approval Process: CanaQuest is positioned to submit New Drug Applications (NDAs) to Health Canada and the US FDA for Phase II/III clinical trials. Approval is projected to take approximately 2 years in Canada and 3 years in the US. The company acknowledges the inherent risks and uncertainties involved in the regulatory approval process, including regulatory requirements, clinical trial outcomes, and potential unforeseen challenges.
Partnerships: CanaQuest has established partnerships with Neeka Health for clinical trial expertise and the NHL Alumni Association for clinical studies. These partnerships will investigate the potential applications of CQ-001 across various indications, paving the way for future clinical trials.
Awards and Recognition: CanaQuest has been awarded “Endocannabinoid Therapeutics Development Company of the Year 2024” in the ninth annual Healthcare and Pharmaceutical Awards by Global Health & Pharma, UK.
Market Strategy: CanaQuest aims to introduce CQ-001 into markets currently dominated by Epidiolex®. By enhancing CQ-001’s efficacy, the company projects substantial revenues post-approval in the US and Canada. Additionally, CanaQuest is exploring applications beyond epilepsy, including inflammation-related conditions and veterinary pharmaceuticals.
Exit Strategy: The company’s exit strategy includes an uplisting and/or a large pharma buyout. A notable precedent is GW Pharma, which was bought by Jazz Pharma for $7.2 billion.
Investment Opportunity: Despite the challenges and risks associated with the regulatory approval process, CanaQuest’s comprehensive strategy, coupled with the expertise of its management and consultants, positions the company well to navigate the regulatory landscape and achieve its objectives, making it a compelling investment opportunity.
Private Placement: The Company is having discussions.
Please reach out to learn more.
Paul Ramsay, CEO & Co-founder
Dir: 416-704-3040
paul@canaquest.com
www.canaquest.com
Cautionary statement regarding forward-looking information:
This Overview contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on current expectations, estimates, forecasts, and projections about the industry in which CanaQuest Medical Corp operates and the beliefs and assumptions of the management of CanaQuest. Forward-looking statements may be identified by the use of forward-looking terminology such as “plans,” “expects,” “believes,” “estimates,” “intends,” “may,” “will,” “should,” “could,” “anticipates,” “predicts,” “potential,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements include but are not limited to, statements regarding:
- The anticipated benefits and effectiveness of Drug Candidate, CQ-001, and its potential to treat rare neurological conditions of epilepsy.
- The expected progress and outcomes of clinical trials for CQ-001 and the nutraceutical formulation, Mentanine™.
- CanaQuest’s ability to navigate the regulatory approval process
- The potential for commercialization of cannabidiol-based pharmaceuticals and
- The impact of the executive team appointments on CanaQuest’s clinical trials and regulatory approval
These forward-looking statements are subject to a number of risks, uncertainties, and assumptions about CanaQuest Medical Corp, and there can be no assurance that the expectations of CanaQuest will be realized. Important factors that could cause actual results to differ materially from those in the forward-looking statements include:
- The possibility that clinical trials of CQ-001 may not be successful or may take longer than anticipated to
- Challenges in securing regulatory approvals or changes in the regulatory
- The potential for unforeseen side effects or other safety issues that could interrupt or halt clinical trials or affect patient enrollment.
- The ability to protect intellectual property and to operate without infringing upon the proprietary rights of
- Market acceptance of the Company’s products and competition from existing products or new products that may
- The impact of economic, competitive, governmental, technological, or other factors on the pharmaceutical and nutraceutical markets that could affect the Company’s operations or financial results.
- The company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated, and the results, cost, and timing of the company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation, may not be as expected.
Investors are cautioned that any forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. CanaQuest Medical Corp undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.